Debra Times Seven for Sanofi-Aventis ADME Research
News Nov 08, 2007
The company is running the latest release of Debra (5.6.3) on a Citrix server in its Global Metabolism & Pharmacokinetic Department in Montpellier, with connections to Chilly-Mazarin, Alfortville, Frankfurt, Budapest and Bridgewater USA.
It has taken three years to implement the programme, beginning in 2004 with the decision to centralize and the choice of Debra as the LIMS best suited to meeting the needs of the different sites. User requirement specifications were drawn up in 2005 for development by LabLogic the following year. The system was validated in the first half of 2007 in time for implementation in June.
The harmonization resolves inconsistencies in LIMS practices following the Sanofi-Synthelabo / Aventis merger, as a result of which some sites had more experience of Debra than others and two were using different systems entirely.
"We anticipate that standardizing on Debra will reduce costs and help us to follow the same studies procedures at all our sites, but the biggest advantage is likely to be the sharing of data," said Valerie Gall of the Montpellier GMPK.
"With all our ADME compound information on a single database we will be able to compare studies from different sites quickly and easily."
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE